Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jan 22 2021 | Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Industry News Industry Read More Jan 13 2021 | US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Industry News In The News Industry Read More Oct 27 2020 | New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status Industry News Industry Read More Oct 13 2020 | Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Industry News Industry Read More Oct 5 2020 | Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »
Jan 22 2021 | Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Industry News Industry Read More
Jan 13 2021 | US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Industry News In The News Industry Read More
Oct 27 2020 | New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status Industry News Industry Read More
Oct 13 2020 | Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Industry News Industry Read More
Oct 5 2020 | Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Industry News In The News Industry Read More
